An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis

NCT01384162 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped Issues with development and supply of infusion system for delivery of IMP. Lack of favorable benefit risk ratio in sNN0029-003 study (review of interim data).

Conditions

Interventions

Sponsor

Newron Sweden AB

Collaborators